医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SpeeDx Partners with Nepean Hospital to Commercialise Respiratory Virus Host Biomarker Assay

2020年11月09日 PM10:00
このエントリーをはてなブックマークに追加


 

SYDNEY

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has partnered with researchers from Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital in an exclusive agreement to commercialise a host gene expression biomarker test for respiratory viral illness. Expression of the patented biomarker, IFI27, as discovered by NBMLHD Drs Anthony Maclean, Benjamin Tang and colleagues, is strongly correlated with disease progression in Influenza1 and COVID-19 patients2. The commercial assay will be positioned to support clinicians facing difficult triage or patient management decisions, supporting risk-based stratification of patients presenting with respiratory viral illness, including COVID-19.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005432/en/

SpeeDx newly patented InSignia technology simplifies the measurement of gene expression and will underpin the creation of a simple, standardized biomarker test to support management of patients with respiratory viral illness. (Photo: Business Wire)

SpeeDx newly patented InSignia technology simplifies the measurement of gene expression and will underpin the creation of a simple, standardized biomarker test to support management of patients with respiratory viral illness. (Photo: Business Wire)

“Host biomarkers are important indicators of a patient’s response to an infection,” said Professor Maclean, from the Nepean Hospital’s Intensive Care Unit. “Markers linked to viral specific immune responses, such as IFI27 – an interferon stimulating gene – are particularly informative. When they get switched on, it tells all the other immune cells to come and fight the virus. Levels of this specific marker, measured in the blood, have been shown to be directly correlated to progression of respiratory viral illness.”

The SpeeDx biomarker test utilises newly patented InSigniaTM technology that enhances the measurement of gene expression and is designed to run on standard laboratory equipment, allowing for expedited development and rapid adoption in high- and low-throughput hospital settings.

“The availability of a simple diagnostic test that can accurately differentiate viral from bacterial causes of pulmonary disease, using a single-gene host biomarker, would transform patient management,” said Dr. Charles Cartwright, SpeeDx VP of Scientific Affairs. “Coupled with a pathogen detection assay and other disease indicators, this test can not only stratify patients based on risk of adverse disease progression, changes in the level of biomarker over time can inform more accurate prognoses and guide ongoing patient management decisions.”

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com

About Nepean Blue Mountains Local Health District

Nepean Blue Mountains Local Health District is well placed to draw on over 100 years of continuously caring for the community, conducting research and delivering innovation. The Nepean Hospital Intensive Care Unit is part of NBMLHD’s 5,700-strong staff. Being on the frontline of health means NBMLHD has a focus on practical solutions that deliver maximum impact to the health and wellbeing of patients and their families.

References

  1. Tang BM et al. Eur Respir J. 2017 Jun 15;49(6):1602098.
  2. https://www.smh.com.au/national/covid-19-blood-test-to-predict-which-patients-will-need-the-most-care-20200406-p54hja.html

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005432/en/

CONTACT

SpeeDx

Australia, New Zealand and Europe

Madeline O’Donoghue – SpeeDx

+61 406 582 808

United States

Rick Roose – RCI Healthcare Public Relations

+1 415 202 4445

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • エクセンシア、2022年第1四半期財務業績を2022年5月25日に報告
  • Anterra Capital:疫情和食品价格通胀激发了投资者对于加快食品和农业部门转型的兴趣
  • サーモの調査で、今年のASCOに参加するがん専門医が最も関心を寄せているのは肺がん・乳がんの新研究であることが判明
  • デンタル・モニタリングが包括的で生涯を通じた患者体験のための仮想診療プラットフォームを発表
  • Dental Monitoring推出虚拟诊疗平台,提供全方位的终身患者体验